

Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentrinelsystem.org.

Overview for Request MSY4_MPR59_v1, Report 2 of 2

Request ID: MSY4_MPR59_v1

Request Description: This request estimates prevalent and incident use of acetaminophen with codeine, acyclovir/acyclovir sodium, nizatidine, albuterol/albuterol sulfate, levalbuterol HCl/levalbuterol tartrate, oxycodone HCl, nitazoxanide, and sucralfate among children aged 0-2 years. This report contains the results where both medical and drug coverage was required. This is report 2 of 2. The first report contains results where only drug coverage was required.

Modular Program Tool Used: Modular Program #9 (MP9) version 2.0

Data Source: We distributed this request on September 10, 2013 to 18 Data Partners contributing to the Mini-Sentinel Distributed Database (MSDD). The study period included data from January 1, 2000 - December 31, 2012. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified prevalent and incident users of acetaminophen with codeine, acyclovir/acyclovir sodium, nizatidine, albuterol/albuterol sulfate, levalbuterol HCl/levalbuterol tartrate, oxycodone HCl, nitazoxanide, and sucralfate, among a cohort aged 0-2 years.

Exposure of Interest: We identified exposures of interest using valid National Drug Codes (NDCs) identified from outpatient pharmacy dispensing recorded in the Mini-Sentinel Common Data Model (MSCDM). We defined incident use as no prior evidence of exposure drugs in the day prior to the first qualifying exposure (index). Cohort re-entry was not allowed. Only the first incident exposure for each member over the member's entire enrollment history was included. Please see Appendix B for a list of generic and brand drug names used to define exposures in this request.

Cohort Eligibility Criteria: We required members to be continuously enrolled in health plans with both medical and drug coverage, during which gaps in coverage of up to 45 days were allowed. The following age groups were included in this cohort: 0-12 months and 12-24 months. The 0-12 month age group was further stratified by 0-<1, 1-<3, 3-<6, and 6-<12 months.

Please see Appendix C for the specifications of parameters used in the analyses for this request.

Limitations: Algorithms to define exposures may be imperfect and therefore, may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table of Contents

Glossary List of Terms Found in this Report and their Definitions

Table 1 Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug

Figure 1a Number of Prevalent Users and Dispensings among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug Product

Figure 1b Prevalent Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug Product

Table 2 Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug

Figure 2a Number of New Users and Dispensings among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug Product

Figure 2b Incident Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug Product

Table 3a Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Age Group

Table 3b Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Age Group

Table 4a Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Sex

Table 4b Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Sex

Table 5a Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

Table 5b Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

Appendix A Dates of Available Data for Each Data Partner (DP) in the Mini-Sentinel Distributed Database (MSDD) as of Request Send Date (September 10, 2013)

Appendix B List of Generic and Brand Drug Names Used to Define Exposures in this Request

Appendix C Specifications Defining Parameters for this Request

Glossary of Terms in Modular Program 9*

Amount Supplied - Number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt" value in the Mini-Sentinel Common Data Model (MSCDM).

"Incident with Respect to" Codes - NDC and/or procedure and/or diagnosis codes to be used to refine the incident definition for the exposure(s) of interest. For example, if a requester is examining exposure to DRUG A but wants incidence of DRUG A to be defined with respect to DRUG A and DRUG B, the Incident with Respect to Code fields would include both DRUG A and DRUG B codes.

Care Setting - Contains the care settings considered for the individual diagnosis or procedure codes of interest. The following are valid entries:

IP: inpatient hospital stays

IS: non-acute institutional stays

ED: emergency department visits

AV: ambulatory visits

OA: other ambulatory visits.

Days Supplied - Number of days supplied for all dispensings encountered by individuals in the prevalent or incident cohort. The number is reported by the pharmacist as the number of days that the medications supports, based on the number of doses. (To be included in the incident-based cohort, a member must have a dispensing that meets the criteria specified for incidence type and washout period. However, if a member has more than one dispensings claim on the index date, all claims identified on that date will be included in the number of dispensings. Claims identified any time after the index date are not included in dispensings.)

Dispensings - Total number of dispensings for members included in the prevalent- or incident-based cohort. To be included in the incident-based cohort, a member must have a dispensing that meets the criteria specified for incidence type and washout period. However, if a member has more than one dispensings claim on the index date, all claims identified on that date will be included in the number of dispensings. Claims identified any time after the index date are not included in dispensings.

Eligible Members (incidence-based cohort) - Number of members eligible for incident diagnosis (defined by the washout period) with drug and/or medical coverage during the query period.

Eligible Members (prevalence-based cohort) - Number of members with at least one day of drug and/or medical coverage during the query period.

Enrollment Gap - Number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Exposure - NDC and/or procedure and/or diagnosis code values for the exposure(s) of interest.

Incidence Type (incidence-based cohort) - *Minimum incidence type* will only consider the first claim in the query period as long as it is the first claim in the user's entire available history. *Single incidence type* will consider the first claim in the query period that satisfies the washout period criteria. That is, incidence is defined as the first claim during the query period with no evidence of a prior claim during the previous washout period days. *Multiple incidence type* will use the washout period to establish incidence and consider all qualifying incident claims.

Incident Only Care Setting - Contains the care settings considered for the individual diagnosis or procedure codes included as "Incident with Respect to" codes.

Member-Years (incidence-based cohort) - Sum of all years of enrollment with drug and/or medical coverage in the query period preceded by a washout period.

Member-Years (prevalence-based cohort) - Sum of all years members are enrolled with drug and/or medical coverage during the query period.

New Starts - Number of incident dispensings during the query period. Patient must have no prior dispensings of interest in the washout period. For a single and minimum incidence type, an individual may have no more than one new start. For a multiple incidence type, an individual may have more than one new start.

New Users - Number of members with incident claims during the query period. Member must have no evidence of claims of interest (defined by incidence criteria) in the prior washout period. A patient may only be counted once in a query period.

Query Period - Period in which the modular program looks for diagnoses of interest.

Washout Period (incidence-based cohort) - Number of days a patient is required to have no evidence of prior claim of interest and continuous drug and/or medical coverage.

*all terms may not be used in this report

Table 1. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per			
						1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing
Acetaminophen with codeine	111,363	126,417	941,812	6,527,209	6,869,628	17.06	8.46	1.14	7.45
Acyclovir/acyclovir sodium	21,079	26,786	275,316	6,527,209	6,869,628	3.23	13.06	1.27	10.28
Albuterol/albuterol sulfate	916,720	1,679,243	28,378,176	6,527,209	6,869,628	140.45	30.96	1.83	16.90
Levalbuterol HCl/Levalbuterol tartrate	149,362	281,339	4,342,037	6,527,209	6,869,628	22.88	29.07	1.88	15.43
Nitazoxanide	2,392	2,774	15,857	6,527,209	6,869,628	0.37	6.63	1.16	5.72
Nizatidine	33,402	94,299	2,851,120	6,527,209	6,869,628	5.12	85.36	2.82	30.23
Oxycodone HCl	5,171	6,058	44,890	6,527,209	6,869,628	0.79	8.68	1.17	7.41
Sucralfate	7,746	11,966	265,964	6,527,209	6,869,628	1.19	34.34	1.54	22.23

Figure 1a. Number of Prevalent Users and Dispensings among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug Product




Figure 1b. Prevalent Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug Product




Table 2. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug

	New Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	New Users per			
						1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing
Acetaminophen with codeine	111,297	126,342	941,265	6,515,303	6,780,451	17.08	8.46	1.14	7.45
Acyclovir/acyclovir sodium	21,057	26,755	274,863	6,515,391	6,839,540	3.23	13.05	1.27	10.27
Albuterol/albuterol sulfate	915,537	1,676,739	28,333,521	6,514,144	6,071,662	140.55	30.95	1.83	16.90
Levalbuterol HCl/Levalbuterol tartrate	149,178	280,907	4,334,675	6,515,213	6,717,332	22.90	29.06	1.88	15.43
Nitazoxanide	2,390	2,772	15,851	6,515,419	6,850,832	0.37	6.63	1.16	5.72
Nizatidine	33,342	94,103	2,845,212	6,515,353	6,814,133	5.12	85.33	2.82	30.24
Oxycodone HCl	5,162	6,014	44,055	6,515,386	6,848,616	0.79	8.53	1.17	7.33
Sucralfate	7,739	11,957	265,838	6,515,409	6,845,360	1.19	34.35	1.55	22.23

Figure 2a. Number of New Users and Dispensings among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug Product




Figure 2b. Incident Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug Product




Table 3a. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Age Group

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per			
						1,000 Eligible Members	Days Supplied per User	Dispensing per User	Days Supplied per Dispensing
Acetaminophen with codeine									
0 - < 12 Months	35,609	38,730	288,363	4,711,366	3,179,640	7.56	8.10	1.09	7.45
0 - < 1 Month	99	101	732	3,103,623	228,805	0.03	7.39	1.02	7.25
1 - < 3 Months	1,490	1,544	12,797	3,327,518	499,893	0.45	8.59	1.04	8.29
3 - < 6 Months	5,668	5,934	45,679	3,504,248	779,831	1.62	8.06	1.05	7.70
6 - < 12 Months	29,171	31,151	229,155	4,191,283	1,725,293	6.96	7.86	1.07	7.36
12 - < 24 Months	79,184	87,687	653,449	5,018,598	3,493,643	15.78	8.25	1.11	7.45
Acyclovir/acyclovir sodium									
0 - < 12 Months	5,647	7,606	95,073	4,711,366	3,179,640	1.20	16.84	1.35	12.50
0 - < 1 Month	112	114	2,238	3,103,623	228,805	0.04	19.98	1.02	19.63
1 - < 3 Months	424	566	11,137	3,327,518	499,893	0.13	26.27	1.33	19.68
3 - < 6 Months	1,079	1,462	22,713	3,504,248	779,831	0.31	21.05	1.35	15.54
6 - < 12 Months	4,488	5,464	58,985	4,191,283	1,725,293	1.07	13.14	1.22	10.80
12 - < 24 Months	16,026	19,180	180,243	5,018,598	3,493,643	3.19	11.25	1.20	9.40
Albuterol/albuterol sulfate									
0 - < 12 Months	535,326	815,490	13,682,219	4,711,366	3,179,640	113.62	25.56	1.52	16.78
0 - < 1 Month	2,329	2,435	43,834	3,103,623	228,805	0.75	18.82	1.05	18.00
1 - < 3 Months	50,295	57,340	982,968	3,327,518	499,893	15.11	19.54	1.14	17.14
3 - < 6 Months	189,266	237,575	3,972,095	3,504,248	779,831	54.01	20.99	1.26	16.72
6 - < 12 Months	372,290	518,140	8,683,322	4,191,283	1,725,293	88.82	23.32	1.39	16.76
12 - < 24 Months	547,398	863,753	14,695,957	5,018,598	3,493,643	109.07	26.85	1.58	17.01
Levalbuterol HCl/Levalbuterol tartrate									
0 - < 12 Months	93,099	148,816	2,239,337	4,711,366	3,179,640	19.76	24.05	1.60	15.05
0 - < 1 Month	673	701	9,894	3,103,623	228,805	0.22	14.70	1.04	14.11
1 - < 3 Months	12,181	14,217	206,183	3,327,518	499,893	3.66	16.93	1.17	14.50
3 - < 6 Months	35,635	46,145	684,566	3,504,248	779,831	10.17	19.21	1.29	14.84
6 - < 12 Months	61,024	87,753	1,338,694	4,191,283	1,725,293	14.56	21.94	1.44	15.26
12 - < 24 Months	81,754	132,523	2,102,700	5,018,598	3,493,643	16.29	25.72	1.62	15.87

Table 3a. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Age Group

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per			
						1,000 Eligible Members	Days Supplied per User	Dispensing per User	Days Supplied per Dispensing
Nitazoxanide									
0 - < 12 Months	429	470	2,989	4,711,366	3,179,640	0.09	6.97	1.10	6.36
0 - < 1 Month	0	0	0	3,103,623	228,805	0.00	---	---	---
1 - < 3 Months	23	24	191	3,327,518	499,893	0.01	8.30	1.04	7.96
3 - < 6 Months	63	68	543	3,504,248	779,831	0.02	8.62	1.08	7.99
6 - < 12 Months	352	378	2,255	4,191,283	1,725,293	0.08	6.41	1.07	5.97
12 - < 24 Months	1,990	2,304	12,868	5,018,598	3,493,643	0.40	6.47	1.16	5.59
Nizatidine									
0 - < 12 Months	31,436	84,232	2,545,876	4,711,366	3,179,640	6.67	80.99	2.68	30.22
0 - < 1 Month	3,761	3,809	116,728	3,103,623	228,805	1.21	31.04	1.01	30.65
1 - < 3 Months	18,442	26,275	793,359	3,327,518	499,893	5.54	43.02	1.42	30.19
3 - < 6 Months	15,858	29,873	901,342	3,504,248	779,831	4.53	56.84	1.88	30.17
6 - < 12 Months	10,103	24,275	734,447	4,191,283	1,725,293	2.41	72.70	2.40	30.26
12 - < 24 Months	3,793	10,067	305,244	5,018,598	3,493,643	0.76	80.48	2.65	30.32
Oxycodone HCl									
0 - < 12 Months	2,528	2,851	20,622	4,711,366	3,179,640	0.54	8.16	1.13	7.23
0 - < 1 Month	118	126	770	3,103,623	228,805	0.04	6.53	1.07	6.11
1 - < 3 Months	218	234	1,816	3,327,518	499,893	0.07	8.33	1.07	7.76
3 - < 6 Months	667	715	5,364	3,504,248	779,831	0.19	8.04	1.07	7.50
6 - < 12 Months	1,617	1,776	12,672	4,191,283	1,725,293	0.39	7.84	1.10	7.14
12 - < 24 Months	2,791	3,207	24,268	5,018,598	3,493,643	0.56	8.70	1.15	7.57
Sucralfate									
0 - < 12 Months	4,881	7,657	186,578	4,711,366	3,179,640	1.04	38.23	1.57	24.37
0 - < 1 Month	205	213	4,837	3,103,623	228,805	0.07	23.60	1.04	22.71
1 - < 3 Months	1,655	2,011	50,553	3,327,518	499,893	0.50	30.55	1.22	25.14
3 - < 6 Months	1,855	2,543	65,227	3,504,248	779,831	0.53	35.16	1.37	25.65
6 - < 12 Months	2,050	2,890	65,961	4,191,283	1,725,293	0.49	32.18	1.41	22.82
12 - < 24 Months	3,181	4,309	79,386	5,018,598	3,493,643	0.63	24.96	1.35	18.42

Table 3b. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Age Group

	New Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per			
							1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing
Acetaminophen with codeine										
0 - < 12 Months	35,587	35,587	38,707	288,111	4,702,381	3,156,691	7.57	8.10	1.09	7.44
0 - < 1 Month										
1 - < 3 Months										
3 - < 6 Months										
6 - < 12 Months										
12 - < 24 Months	75,710	75,710	82,806	615,609	4,979,581	3,428,065	15.20	8.13	1.09	7.43
Acyclovir/acyclovir sodium										
0 - < 12 Months	5,640	5,640	7,590	94,764	4,702,404	3,165,056	1.20	16.80	1.35	12.49
0 - < 1 Month										
1 - < 3 Months										
3 - < 6 Months										
6 - < 12 Months										
12 - < 24 Months	15,417	15,417	17,675	153,147	5,006,873	3,478,266	3.08	9.93	1.15	8.66
Albuterol/albuterol sulfate										
0 - < 12 Months	534,631	534,631	814,309	13,660,589	4,701,767	2,964,528	113.71	25.55	1.52	16.78
0 - < 1 Month										
1 - < 3 Months										
3 - < 6 Months										
6 - < 12 Months										
12 - < 24 Months	380,906	380,906	545,138	9,184,872	4,543,319	2,922,628	83.84	24.11	1.43	16.85
Levalbuterol HCl/Levalbuterol tartrate										
0 - < 12 Months	92,992	92,992	148,625	2,236,179	4,702,317	3,128,261	19.78	24.05	1.60	15.05
0 - < 1 Month										
1 - < 3 Months										
3 - < 6 Months										
6 - < 12 Months										
12 - < 24 Months	56,186	56,186	82,514	1,279,487	4,929,619	3,394,715	11.40	22.77	1.47	15.51

Table 3b. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Age Group

	New Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per			
							1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing
Nitazoxanide										
0 - < 12 Months	429	429	470	2,989	4,702,415	3,166,521	0.09	6.97	1.10	6.36
0 - < 1 Month										
1 - < 3 Months										
3 - < 6 Months										
6 - < 12 Months										
12 - < 24 Months	1,961	1,961	2,266	12,627	5,011,559	3,487,969	0.39	6.44	1.16	5.57
Nizatidine										
0 - < 12 Months	31,382	31,382	84,068	2,540,932	4,702,360	3,148,804	6.67	80.97	2.68	30.22
0 - < 1 Month										
1 - < 3 Months										
3 - < 6 Months										
6 - < 12 Months										
12 - < 24 Months	1,960	1,960	4,249	125,961	4,989,511	3,470,517	0.39	64.27	2.17	29.64
Oxycodone HCl										
0 - < 12 Months	2,519	2,519	2,823	20,094	4,702,398	3,165,868	0.54	7.98	1.12	7.12
0 - < 1 Month										
1 - < 3 Months										
3 - < 6 Months										
6 - < 12 Months										
12 - < 24 Months	2,643	2,643	2,964	21,496	5,009,989	3,486,554	0.53	8.13	1.12	7.25
Sucralfate										
0 - < 12 Months	4,878	4,878	7,653	186,544	4,702,411	3,164,361	1.04	38.24	1.57	24.38
0 - < 1 Month										
1 - < 3 Months										
3 - < 6 Months										
6 - < 12 Months										
12 - < 24 Months	2,861	2,861	3,602	60,944	5,008,120	3,484,823	0.57	21.30	1.26	16.92

Table 4a. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Sex

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per 1,000 Eligible Members			
						Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Acetaminophen with codeine									
Female	37,534	42,780	344,061	3,176,974	3,347,114	11.81	9.17	1.14	8.04
Male	73,823	83,631	597,718	3,349,746	3,522,105	22.04	8.10	1.13	7.15
Unknown	6	6	33	489	409	12.27	5.50	1.00	5.50
Acyclovir									
Female	10,003	12,580	128,691	3,176,974	3,347,114	3.15	12.87	1.26	10.23
Male	11,074	14,204	146,611	3,349,746	3,522,105	3.31	13.24	1.28	10.32
Unknown	2	2	14	489	409	4.09	7.00	1.00	7.00
Albuterol									
Female	376,166	650,360	11,015,918	3,176,974	3,347,114	118.40	29.28	1.73	16.94
Male	540,516	1,028,813	17,361,149	3,349,746	3,522,105	161.36	32.12	1.90	16.87
Unknown	38	70	1,109	489	409	77.71	29.18	1.84	15.84
Levalbuterol HCl/Levalbuterol tartrate									
Female	60,480	108,429	1,677,289	3,176,974	3,347,114	19.04	27.73	1.79	15.47
Male	88,872	172,894	2,664,460	3,349,746	3,522,105	26.53	29.98	1.95	15.41
Unknown	10	16	288	489	409	20.45	28.80	1.60	18.00
Nitazoxanide									
Female	1,025	1,192	6,688	3,176,974	3,347,114	0.32	6.52	1.16	5.61
Male	1,367	1,582	9,169	3,349,746	3,522,105	0.41	6.71	1.16	5.80
Unknown	0	0	0	489	409	0.00	---	---	---
Nizatidine									
Female	15,148	42,515	1,284,571	3,176,974	3,347,114	4.77	84.80	2.81	30.21
Male	18,245	51,766	1,565,958	3,349,746	3,522,105	5.45	85.83	2.84	30.25
Unknown	9	18	591	489	409	18.40	65.67	2.00	32.83
Oxycodone HCl									
Female	1,729	2,097	16,923	3,176,974	3,347,114	0.54	9.79	1.21	8.07
Male	3,442	3,961	27,967	3,349,746	3,522,105	1.03	8.13	1.15	7.06
Unknown	0	0	0	489	409	0.00	---	---	---

Table 4a. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Sex

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per 1,000 Eligible Members			
						Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Sucralfate									
Female	3,467	5,228	115,436	3,176,974	3,347,114	1.09	33.30	1.51	22.08
Male	4,279	6,738	150,528	3,349,746	3,522,105	1.28	35.18	1.57	22.34
Unknown	0	0	0	489	409	0.00	---	---	---

Table 4b. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Sex

	New Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing
Acetaminophen with codeine										
Female	37,502	37,502	42,743	343,723	3,171,249	3315816	11.83	9.17	1.14	8.04
Male	73,789	73,789	83,593	597,509	3,343,565	3464229	22.07	8.10	1.13	7.15
Unknown	6	6	6	33	489	406	12.27	5.50	1.00	5.50
Acyclovir										
Female	9,987	9,987	12,555	128,281	3,171,293	3332684	3.15	12.84	1.26	10.22
Male	11,068	11,068	14,198	146,568	3,343,609	3506448	3.31	13.24	1.28	10.32
Unknown	2	2	2	14	489	407	4.09	7.00	1.00	7.00
Albuterol										
Female	375,707	375,707	649,335	10,997,097	3,170,807	3022994	118.49	29.27	1.73	16.94
Male	539,792	539,792	1,027,334	17,335,315	3,342,848	3048289	161.48	32.11	1.90	16.87
Unknown	38	38	70	1,109	489	380	77.71	29.18	1.84	15.84
Levalbuterol HCl/Levalbuterol tartrate										
Female	60,419	60,419	108,304	1,675,233	3,171,241	3284285	19.05	27.73	1.79	15.47
Male	88,749	88,749	172,587	2,659,154	3,343,483	3432645	26.54	29.96	1.94	15.41
Unknown	10	10	16	288	489	402	20.45	28.80	1.60	18.00
Nitazoxanide										
Female	1,023	1,023	1,190	6,682	3,171,308	3338022	0.32	6.53	1.16	5.62
Male	1,367	1,367	1,582	9,169	3,343,622	3512402	0.41	6.71	1.16	5.80
Unknown	0	0	0	0	489	408	0.00	---	---	---
Nizatidine										
Female	15,123	15,123	42,435	1,282,230	3,171,281	3321287	4.77	84.79	2.81	30.22
Male	18,210	18,210	51,650	1,562,391	3,343,583	3492448	5.45	85.80	2.84	30.25
Unknown	9	9	18	591	489	397	18.40	65.67	2.00	32.83
Oxycodone HCl										
Female	1,723	1,723	2,065	16,264	3,171,285	3337453	0.54	9.44	1.20	7.88
Male	3,439	3,439	3,949	27,791	3,343,612	3510755	1.03	8.08	1.15	7.04
Unknown	0	0	0	0	489	408	0.00	---	---	---

Table 4b. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Sex

	New Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Years	New Users per			
							1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing
Sucralfate										
Female	3,464	3,464	5,223	115,356	3,171,307	3335635	1.09	33.30	1.51	22.09
Male	4,275	4,275	6,734	150,482	3,343,613	3509318	1.28	35.20	1.58	22.35
Unknown	0	0	0	0	489	408	0.00	---	---	---

Table 5a. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing
Acetaminophen with codeine									
2000	5,442	6,258	60,919	381,038	222,808	14.28	11.19	1.15	9.73
2001	5,259	5,986	59,506	369,094	219,915	14.25	11.32	1.14	9.94
2002	5,281	5,991	57,993	367,403	218,640	14.37	10.98	1.13	9.68
2003	5,222	5,983	56,535	364,082	216,014	14.34	10.83	1.15	9.45
2004	4,335	4,769	35,990	391,249	229,889	11.08	8.30	1.10	7.55
2005	5,135	5,741	40,283	408,029	240,560	12.58	7.84	1.12	7.02
2006	9,967	10,995	81,731	866,997	490,388	11.50	8.20	1.10	7.43
2007	9,769	10,641	76,570	938,481	519,735	10.41	7.84	1.09	7.20
2008	17,470	18,829	124,776	1,881,177	1,033,764	9.29	7.14	1.08	6.63
2009	15,699	16,896	113,015	1,764,019	986,151	8.90	7.20	1.08	6.69
2010	13,452	14,574	98,947	1,615,161	908,828	8.33	7.36	1.08	6.79
2011	11,064	11,886	81,053	1,519,620	855,212	7.28	7.33	1.07	6.82
2012	7,434	7,868	54,494	1,368,850	727,724	5.43	7.33	1.06	6.93
Acyclovir									
2000	511	629	9,233	381,038	222,808	1.34	18.07	1.23	14.68
2001	556	698	9,747	369,094	219,915	1.51	17.53	1.26	13.96
2002	625	780	10,437	367,403	218,640	1.70	16.70	1.25	13.38
2003	612	796	12,010	364,082	216,014	1.68	19.62	1.30	15.09
2004	723	930	10,385	391,249	229,889	1.85	14.36	1.29	11.17
2005	764	1,004	12,480	408,029	240,560	1.87	16.34	1.31	12.43
2006	1,614	1,975	20,538	866,997	490,388	1.86	12.72	1.22	10.40
2007	1,664	2,068	20,334	938,481	519,735	1.77	12.22	1.24	9.83
2008	3,380	4,027	36,942	1,881,177	1,033,764	1.80	10.93	1.19	9.17
2009	3,128	3,750	35,187	1,764,019	986,151	1.77	11.25	1.20	9.38
2010	3,068	3,747	35,383	1,615,161	908,828	1.90	11.53	1.22	9.44
2011	2,794	3,437	33,071	1,519,620	855,212	1.84	11.84	1.23	9.62
2012	2,445	2,945	29,569	1,368,850	727,724	1.79	12.09	1.20	10.04

Table 5a. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per 1,000 Eligible Members			
						Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Albuterol									
2000	49,794	83,597	1,645,674	381,038	222,808	130.68	33.05	1.68	19.69
2001	50,814	84,484	1,636,337	369,094	219,915	137.67	32.20	1.66	19.37
2002	48,011	78,846	1,536,386	367,403	218,640	130.68	32.00	1.64	19.49
2003	45,382	73,235	1,415,922	364,082	216,014	124.65	31.20	1.61	19.33
2004	40,279	62,029	1,122,387	391,249	229,889	102.95	27.87	1.54	18.09
2005	43,908	68,169	1,226,296	408,029	240,560	107.61	27.93	1.55	17.99
2006	77,657	116,368	2,034,762	866,997	490,388	89.57	26.20	1.50	17.49
2007	78,138	117,406	2,035,747	938,481	519,735	83.26	26.05	1.50	17.34
2008	147,313	216,100	3,436,454	1,881,177	1,033,764	78.31	23.33	1.47	15.90
2009	146,650	217,429	3,460,468	1,764,019	986,151	83.13	23.60	1.48	15.92
2010	138,367	206,411	3,268,441	1,615,161	908,828	85.67	23.62	1.49	15.83
2011	129,795	193,614	3,016,143	1,519,620	855,212	85.41	23.24	1.49	15.58
2012	110,206	161,555	2,543,159	1,368,850	727,724	80.51	23.08	1.47	15.74
Levalbuterol HCl/Levalbuterol tartrate									
2000	241	371	5,614	381,038	222,808	0.63	23.29	1.54	15.13
2001	905	1,621	20,685	369,094	219,915	2.45	22.86	1.79	12.76
2002	1,983	3,635	48,420	367,403	218,640	5.40	24.42	1.83	13.32
2003	4,122	6,958	99,452	364,082	216,014	11.32	24.13	1.69	14.29
2004	6,093	9,847	168,438	391,249	229,889	15.57	27.64	1.62	17.11
2005	7,302	12,693	196,068	408,029	240,560	17.90	26.85	1.74	15.45
2006	16,814	27,024	426,900	866,997	490,388	19.39	25.39	1.61	15.80
2007	17,820	27,886	431,287	938,481	519,735	18.99	24.20	1.56	15.47
2008	37,400	57,966	861,485	1,881,177	1,033,764	19.88	23.03	1.55	14.86
2009	32,656	50,674	792,688	1,764,019	986,151	18.51	24.27	1.55	15.64
2010	22,613	34,514	544,524	1,615,161	908,828	14.00	24.08	1.53	15.78
2011	19,338	29,648	460,739	1,519,620	855,212	12.73	23.83	1.53	15.54
2012	12,447	18,502	285,737	1,368,850	727,724	9.09	22.96	1.49	15.44

Table 5a. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per 1,000 Eligible Members			
						Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Nitazoxanide									
2000	0	0	0	381,038	222,808	0.00	---	---	---
2001	0	0	0	369,094	219,915	0.00	---	---	---
2002	0	0	0	367,403	218,640	0.00	---	---	---
2003	6	10	113	364,082	216,014	0.02	18.83	1.67	11.30
2004	32	38	248	391,249	229,889	0.08	7.75	1.19	6.53
2005	82	94	610	408,029	240,560	0.20	7.44	1.15	6.49
2006	260	309	1,889	866,997	490,388	0.30	7.27	1.19	6.11
2007	254	296	1,824	938,481	519,735	0.27	7.18	1.17	6.16
2008	617	679	3,461	1,881,177	1,033,764	0.33	5.61	1.10	5.10
2009	425	481	2,658	1,764,019	986,151	0.24	6.25	1.13	5.53
2010	367	430	2,468	1,615,161	908,828	0.23	6.72	1.17	5.74
2011	255	294	1,621	1,519,620	855,212	0.17	6.36	1.15	5.51
2012	124	143	965	1,368,850	727,724	0.09	7.78	1.15	6.75
Nizatidine									
2000	0	0	0	381,038	222,808	0.00	---	---	---
2001	0	0	0	369,094	219,915	0.00	---	---	---
2002	1	1	14	367,403	218,640	0.00	14.00	1.00	14.00
2003	1	1	30	364,082	216,014	0.00	30.00	1.00	30.00
2004	15	21	546	391,249	229,889	0.04	36.40	1.40	26.00
2005	112	248	6,066	408,029	240,560	0.27	54.16	2.21	24.46
2006	1,965	4,354	145,195	866,997	490,388	2.27	73.89	2.22	33.35
2007	3,601	8,634	269,799	938,481	519,735	3.84	74.92	2.40	31.25
2008	10,483	25,625	762,716	1,881,177	1,033,764	5.57	72.76	2.44	29.76
2009	8,078	19,989	599,525	1,764,019	986,151	4.58	74.22	2.47	29.99
2010	5,821	14,534	436,904	1,615,161	908,828	3.60	75.06	2.50	30.06
2011	4,643	11,974	362,610	1,519,620	855,212	3.06	78.10	2.58	30.28
2012	3,554	8,918	267,715	1,368,850	727,724	2.60	75.33	2.51	30.02

Table 5a. Summary of Prevalent Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Years	Users per 1,000 Eligible Members			
						Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Oxycodone HCl									
2000	36	41	291	381,038	222,808	0.09	8.08	1.14	7.10
2001	43	44	278	369,094	219,915	0.12	6.47	1.02	6.32
2002	35	38	306	367,403	218,640	0.10	8.74	1.09	8.05
2003	40	42	384	364,082	216,014	0.11	9.60	1.05	9.14
2004	46	61	801	391,249	229,889	0.12	17.41	1.33	13.13
2005	77	95	828	408,029	240,560	0.19	10.75	1.23	8.72
2006	210	267	2,741	866,997	490,388	0.24	13.05	1.27	10.27
2007	261	316	2,647	938,481	519,735	0.28	10.14	1.21	8.38
2008	745	848	6,255	1,881,177	1,033,764	0.40	8.40	1.14	7.38
2009	820	918	6,488	1,764,019	986,151	0.46	7.91	1.12	7.07
2010	972	1,083	7,748	1,615,161	908,828	0.60	7.97	1.11	7.15
2011	1,032	1,161	7,954	1,519,620	855,212	0.68	7.71	1.13	6.85
2012	1,034	1,144	8,169	1,368,850	727,724	0.76	7.90	1.11	7.14
Sucralfate									
2000	78	114	2,402	381,038	222,808	0.20	30.79	1.46	21.07
2001	87	123	2,642	369,094	219,915	0.24	30.37	1.41	21.48
2002	140	193	4,304	367,403	218,640	0.38	30.74	1.38	22.30
2003	182	284	6,143	364,082	216,014	0.50	33.75	1.56	21.63
2004	248	336	7,140	391,249	229,889	0.63	28.79	1.35	21.25
2005	161	245	4,628	408,029	240,560	0.39	28.75	1.52	18.89
2006	481	719	17,462	866,997	490,388	0.55	36.30	1.49	24.29
2007	611	876	19,764	938,481	519,735	0.65	32.35	1.43	22.56
2008	1,461	2,145	48,490	1,881,177	1,033,764	0.78	33.19	1.47	22.61
2009	1,320	1,884	42,108	1,764,019	986,151	0.75	31.90	1.43	22.35
2010	1,310	1,888	41,259	1,615,161	908,828	0.81	31.50	1.44	21.85
2011	1,192	1,790	39,936	1,519,620	855,212	0.78	33.50	1.50	22.31
2012	940	1369	29686	1368850	727724	0.69	31.58	1.46	21.68

Table 5b. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

	New Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Years	New Users per 1,000 Eligible Members			
							Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Acetaminophen with codeine										
2000	5,429	5,429	6,241	60,753	380,291	219,689	14.28	11.19	1.15	9.73
2001	4,951	4,951	5,561	55,927	365,358	215,952	13.55	11.30	1.12	10.06
2002	4,992	4,992	5,603	54,572	363,525	214,707	13.73	10.93	1.12	9.74
2003	4,885	4,885	5,470	52,210	360,255	212,194	13.56	10.69	1.12	9.54
2004	4,128	4,128	4,496	33,217	387,493	226,494	10.65	8.05	1.09	7.39
2005	4,873	4,873	5,394	37,473	404,636	236,796	12.04	7.69	1.11	6.95
2006	9,727	9,727	10,681	79,403	862,138	483,593	11.28	8.16	1.10	7.43
2007	9,334	9,334	10,072	71,853	930,843	512,188	10.03	7.70	1.08	7.13
2008	17,091	17,091	18,359	121,335	1,868,840	1,021,037	9.15	7.10	1.07	6.61
2009	15,140	15,140	16,227	108,456	1,752,078	973,748	8.64	7.16	1.07	6.68
2010	12,948	12,948	13,919	93,893	1,604,241	897,792	8.07	7.25	1.07	6.75
2011	10,607	10,607	11,305	76,897	1,509,978	845,637	7.02	7.25	1.07	6.80
2012	7,192	7,192	7,578	52,360	1,361,110	720,624	5.28	7.28	1.05	6.91
Acyclovir										
2000	509	509	622	9,046	380,301	221,585	1.34	17.77	1.22	14.54
2001	535	535	632	7,966	368,277	219,106	1.45	14.89	1.18	12.60
2002	610	610	746	9,899	366,649	217,819	1.66	16.23	1.22	13.27
2003	575	575	658	9,067	363,298	215,175	1.58	15.77	1.14	13.78
2004	702	702	880	9,470	390,446	228,983	1.80	13.49	1.25	10.76
2005	728	728	896	10,021	407,157	239,559	1.79	13.77	1.23	11.18
2006	1,581	1,581	1,897	18,517	864,868	487,877	1.83	11.71	1.20	9.76
2007	1,588	1,588	1,920	17,663	935,914	517,439	1.70	11.12	1.21	9.20
2008	3,295	3,295	3,862	33,957	1,873,886	1,028,494	1.76	10.31	1.17	8.79
2009	3,011	3,011	3,483	30,545	1,760,227	982,140	1.71	10.14	1.16	8.77
2010	2,923	2,923	3,397	29,531	1,611,748	905,023	1.81	10.10	1.16	8.69
2011	2,664	2,664	3,152	28,842	1,516,379	851,728	1.76	10.83	1.18	9.15
2012	2,336	2,336	2,707	24,866	1,366,067	724,612	1.71	10.64	1.16	9.19

Table 5b. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

	New Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Years	New Users per 1,000 Eligible Members			
							Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Albuterol										
2000	49,612	49,612	83,183	1,637,505	380,121	196,927	130.52	33.01	1.68	19.69
2001	39,401	39,401	62,240	1,219,321	336,228	180,812	117.19	30.95	1.58	19.59
2002	36,354	36,354	56,921	1,116,709	329,751	179,103	110.25	30.72	1.57	19.62
2003	34,444	34,444	52,772	1,021,598	328,200	179,082	104.95	29.66	1.53	19.36
2004	31,560	31,560	46,523	831,497	357,284	196,171	88.33	26.35	1.47	17.87
2005	34,902	34,902	51,858	931,678	376,736	206,521	92.64	26.69	1.49	17.97
2006	68,208	68,208	99,127	1,725,072	832,895	440,034	81.89	25.29	1.45	17.40
2007	63,357	63,357	90,954	1,563,172	883,312	461,260	71.73	24.67	1.44	17.19
2008	131,555	131,555	188,209	2,966,116	1,818,169	941,390	72.36	22.55	1.43	15.76
2009	120,289	120,289	171,510	2,715,571	1,668,882	879,293	72.08	22.58	1.43	15.83
2010	111,919	111,919	160,412	2,514,262	1,519,594	804,318	73.65	22.47	1.43	15.67
2011	105,466	105,466	151,262	2,331,795	1,430,697	759,397	73.72	22.11	1.43	15.42
2012	88,470	88,470	124,412	1,945,626	1,287,020	647,356	68.74	21.99	1.41	15.64
Levalbuterol HCl/Levalbuterol tartrate										
2000	241	241	371	5,614	380,303	221,702	0.63	23.29	1.54	15.13
2001	824	824	1,452	18,096	368,391	219,027	2.24	21.96	1.76	12.46
2002	1,719	1,719	3,003	39,290	366,298	217,009	4.69	22.86	1.75	13.08
2003	3,653	3,653	5,853	83,198	362,252	213,383	10.08	22.78	1.60	14.21
2004	5,046	5,046	7,851	132,478	387,386	225,102	13.03	26.25	1.56	16.87
2005	5,521	5,521	9,207	140,335	402,329	233,969	13.72	25.42	1.67	15.24
2006	15,077	15,077	23,604	372,074	859,468	478,519	17.54	24.68	1.57	15.76
2007	14,352	14,352	21,421	324,039	924,911	505,240	15.52	22.58	1.49	15.13
2008	33,615	33,615	50,887	755,947	1,861,193	1,007,141	18.06	22.49	1.51	14.86
2009	26,379	26,379	39,232	605,385	1,737,957	958,350	15.18	22.95	1.49	15.43
2010	17,684	17,684	25,845	399,403	1,591,349	886,127	11.11	22.59	1.46	15.45
2011	15,534	15,534	22,905	350,564	1,501,972	837,281	10.34	22.57	1.47	15.31
2012	9,533	9,533	13,534	205,429	1,354,416	714,481	7.04	21.55	1.42	15.18

Table 5b. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

	New Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Years	New Users per 1,000 Eligible Members			
							Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Nitazoxanide										
2000	0	0	0	0	380,303	221,764	0.00	---	---	---
2001	0	0	0	0	368,576	219,473	0.00	---	---	---
2002	0	0	0	0	367,011	218,204	0.00	---	---	---
2003	6	6	10	113	363,719	215,581	0.02	18.83	1.67	11.30
2004	32	32	38	248	390,833	229,380	0.08	7.75	1.19	6.53
2005	81	81	93	604	407,621	240,027	0.20	7.46	1.15	6.49
2006	256	256	305	1,863	865,292	488,558	0.30	7.28	1.19	6.11
2007	249	249	288	1,778	936,740	518,307	0.27	7.14	1.16	6.17
2008	611	611	671	3,411	1,874,776	1,029,896	0.33	5.58	1.10	5.08
2009	416	416	467	2,559	1,761,731	983,714	0.24	6.15	1.12	5.48
2010	364	364	427	2,440	1,613,326	906,665	0.23	6.70	1.17	5.71
2011	252	252	291	1,608	1,517,886	853,195	0.17	6.38	1.15	5.53
2012	123	123	142	958	1,367,483	726,066	0.09	7.79	1.15	6.75
Nizatidine										
2000	0	0	0	0	380,303	221,764	0.00	---	---	---
2001	0	0	0	0	368,576	219,473	0.00	---	---	---
2002	1	1	1	14	367,011	218,204	0.00	14.00	1.00	14.00
2003	1	1	1	30	363,718	215,581	0.00	30.00	1.00	30.00
2004	15	15	21	546	390,836	229,390	0.04	36.40	1.40	26.00
2005	106	106	232	5,666	407,627	240,013	0.26	53.45	2.19	24.42
2006	1,928	1,928	4,216	141,491	865,228	487,784	2.23	73.39	2.19	33.56
2007	3,227	3,227	7,437	229,869	935,245	515,738	3.45	71.23	2.30	30.91
2008	9,867	9,867	23,727	705,865	1,871,358	1,022,871	5.27	71.54	2.40	29.75
2009	6,670	6,670	15,628	467,313	1,753,177	974,357	3.80	70.06	2.34	29.90
2010	4,830	4,830	11,437	343,124	1,604,950	899,181	3.01	71.04	2.37	30.00
2011	3,845	3,845	9,400	284,155	1,511,857	847,686	2.54	73.90	2.44	30.23
2012	2,852	2,852	6,636	199,081	1,362,777	722,091	2.09	69.80	2.33	30.00

Table 5b. Summary of Incident Drug Use among Children 0-2 Years in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2000 and December 31, 2012, by Drug and Year

	New Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Years	New Users per 1,000 Eligible Members			
							Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	
Oxycodone HCl										
2000	36	36	41	291	380,303	221,750	0.09	8.08	1.14	7.10
2001	41	41	42	270	368,550	219,444	0.11	6.59	1.02	6.43
2002	35	35	38	306	366,982	218,174	0.10	8.74	1.09	8.05
2003	39	39	41	378	363,692	215,555	0.11	9.69	1.05	9.22
2004	46	46	61	801	390,809	229,362	0.12	17.41	1.33	13.13
2005	75	75	87	588	407,606	240,015	0.18	7.84	1.16	6.76
2006	203	203	247	2,320	865,279	488,568	0.23	11.43	1.22	9.39
2007	251	251	287	2,215	936,743	518,295	0.27	8.82	1.14	7.72
2008	728	728	816	5,893	1,874,717	1,029,773	0.39	8.09	1.12	7.22
2009	784	784	868	5,993	1,761,570	983,415	0.45	7.64	1.11	6.90
2010	935	935	1,029	7,298	1,612,942	906,198	0.58	7.81	1.10	7.09
2011	998	998	1,115	7,503	1,517,401	852,634	0.66	7.52	1.12	6.73
2012	991	991	1,086	7,589	1,366,830	725,434	0.73	7.66	1.10	6.99
Sucralfate										
2000	78	78	114	2,402	380,303	221,732	0.21	30.79	1.46	21.07
2001	85	85	113	2,342	368,527	219,410	0.23	27.55	1.33	20.73
2002	135	135	182	4,054	366,940	218,117	0.37	30.03	1.35	22.27
2003	166	166	223	4,421	363,615	215,456	0.46	26.63	1.34	19.83
2004	234	234	306	6,376	390,670	229,200	0.60	27.25	1.31	20.84
2005	155	155	227	4,206	407,412	239,866	0.38	27.14	1.46	18.53
2006	473	473	692	16,704	865,181	488,397	0.55	35.32	1.46	24.14
2007	581	581	815	18,179	936,518	517,992	0.62	31.29	1.40	22.31
2008	1,416	1,416	2,056	45,917	1,874,391	1,029,219	0.76	32.43	1.45	22.33
2009	1,233	1,233	1,746	38,467	1,760,964	982,792	0.70	31.20	1.42	22.03
2010	1,211	1,211	1,642	34,140	1,612,389	905,695	0.75	28.19	1.36	20.79
2011	1,117	1,117	1,639	36,196	1,516,945	852,240	0.74	32.40	1.47	22.08
2012	855	855	1,194	25,141	1,366,568	725,245	0.63	29.40	1.40	21.06

Appendix A. Dates of Available Data for Each Data Partner (DP) in the Mini-Sentinel Distributed Database (MSDD) as of Request Send Date (September 10, 2013)

DP ID	DP Start Date*	DP End Date*
DP0001	1/2/2008	11/30/2012
DP0002	1/2/2000	12/31/2012
DP0003	1/2/2000	6/30/2012
DP0004	1/2/2000	12/31/2012
DP0005	1/1/2000	4/30/2012
DP0006	6/2/2007	10/31/2012
DP0007	1/2/2005	12/31/2012
DP0008	1/2/2008	9/30/2012
DP0009	1/2/2000	12/31/2012
DP0010	1/31/2000	12/31/2012
DP0011	1/2/2000	12/31/2011
DP0012	1/1/2000	12/31/2012
DP0013	1/2/2000	6/30/2012
DP0014	1/1/2000	12/31/2012
DP0015	1/31/2000	12/31/2012
DP0016	1/1/2000	12/31/2011
DP0017	1/2/2006	12/31/2012
DP0018	1/31/2004	12/31/2012

*The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.

Appendix B. List of Generic and Brand Drug Names Used to Define Exposures in this Request

Generic Name	Brand Name
Acetaminophen with Codeine	
Acetaminophen with Codeine	Acetaminophen W/Codeine
Acetaminophen with Codeine	Sk-Apap W/Codeine
Acetaminophen with Codeine	Panadol W/Codeine No.3
Acetaminophen with Codeine	Panadol W/Codeine No.4
Acetaminophen with Codeine	Phenaphen W/Codeine
Acetaminophen with Codeine	Tylenol W/Codeine
Acetaminophen with Codeine	Tylenol-Codeine
Acetaminophen with Codeine	Tylenol W/Codeine No.2
Acetaminophen with Codeine	Tylenol-Codeine No.3
Acetaminophen with Codeine	Tylenol W/Codeine No.3
Acetaminophen with Codeine	Tylenol-Codeine No.4
Acetaminophen with Codeine	Tylenol W/Codeine No.4
Acetaminophen with Codeine	Anacin-3 With Codeine
Acetaminophen with Codeine	Anacin-3 W/Codeine
Acetaminophen with Codeine	Codaphen
Acetaminophen with Codeine	Acetaminophen-Codeine
Acetaminophen with Codeine	Proval No.3
Acetaminophen with Codeine	Empracet W/Codeine No.3
Acetaminophen with Codeine	Empracet W/Codeine No.4
Acetaminophen with Codeine	Capital W/Codeine
Acetaminophen with Codeine	Copan
Acetaminophen with Codeine	Capital W-Codeine
Acetaminophen with Codeine	Steraphen W/Codeine
Acetaminophen with Codeine	Acetaminophen With Codeine
Acetaminophen with Codeine	Aceta W/Codeine
Acetaminophen with Codeine	Coastaldyne
Acetaminophen with Codeine	Papa-Deine No.4
Acetaminophen with Codeine	Ty-Pap W/Codeine
Acetaminophen with Codeine	Ty-Tab W/Codeine
Acetaminophen with Codeine	M-Gesic
Acetaminophen with Codeine	Tylagesic 3
Acetaminophen with Codeine	Codaca No.3
Acetaminophen with Codeine	Codaca No.4
Acetaminophen with Codeine	Vitapap W/Codeine
Acetaminophen with Codeine	Stopayne
Acetaminophen with Codeine	Cocet Plus
Acetaminophen with Codeine	Cocet
Acetaminophen with Codeine	Umi-Apap
Acetaminophen with Codeine	An-Abate
Acetaminophen with Codeine	Mi-Code
Acetaminophen with Codeine	Acetaminophen W-Codeine
Acetaminophen with Codeine	Vopac

Appendix B. List of Generic and Brand Drug Names Used to Define Exposures in this Request

Generic Name	Brand Name
Acyclovir	
Acyclovir	Acyclovir
Acyclovir	Zovirax
Nizatidine	
Nizatidine	Axid
Nizatidine	Nizatidine
Nizatidine	Axid AR
Albuterol	
Albuterol	Albuterol
Albuterol Sulfate	Albuterol Sulfate
Albuterol Sulfate	Proventil
Albuterol	Proventil
Albuterol Sulfate	Proventil Hfa
Albuterol	Ventolin
Albuterol Sulfate	Ventolin
Albuterol Sulfate	Ventolin Rotacaps
Albuterol Sulfate	Ventolin Hfa
Albuterol Sulfate	Arm-A-Med (Albuterol Sulfate)
Albuterol Sulfate	Proair Hfa
Albuterol Sulfate	Accuneb
Albuterol Sulfate	Airet
Albuterol Sulfate	Albuterol Sulfate Hfa
Albuterol	Respirol
Albuterol Sulfate	Albuterolsulfate
Albuterol Sulfate	Volmax
Albuterol Sulfate	Vospire Er
Levalbuterol	
Levalbuterol Hcl	Levalbuterol Hcl
Levalbuterol Hcl	Levalbuterol Concentrate
Levalbuterol Tartrate	Xopenex Hfa
Levalbuterol Hcl	Xopenex
Levalbuterol Hcl	Xopenex Concentrate
Oxycodone	
Oxycodone Hcl	Roxicodone
Oxycodone Hcl	Roxicodone Intensol
Oxycodone Hcl	Oxycodone Hcl
Oxycodone Hcl	Oxycodone Concentrate
Oxycodone Hcl	Oxycontin
Oxycodone Hcl	Eth-Oxydose
Oxycodone Hcl	Oxyir
Oxycodone Hcl	Oxyfast
Oxycodone Hcl	Oxecta
Oxycodone Hcl	Endocodone
Oxycodone Hcl	Percolone
Oxycodone Hcl	Dazidox

Appendix B. List of Generic and Brand Drug Names Used to Define Exposures in this Request

Generic Name	Brand Name
Oxycodone Hcl/Acetaminophen	Sk-Oxycodone W/Acetaminophen
Oxycodone Hcl/Acetaminophen	Tylox
Oxycodone Hcl/Acetaminophen	Oxycodone-Acetaminophen
Oxycodone Hcl/Acetaminophen	Roxicet
Oxycodone Hcl/Acetaminophen	Oxycodone W/Acetaminophen
Oxycodone Hcl/Acetaminophen	Percocet
Oxycodone Hcl/Acetaminophen	Oxycodone Hcl-Acetaminophen
Oxycodone Hcl/Acetaminophen	Magnacet
Oxycodone Hcl/Acetaminophen	Endocet
Oxycodone Hcl/Acetaminophen	Xolox
Oxycodone Hcl/Acetaminophen	Primlev
Oxycodone Hcl/Acetaminophen	Oxycodone/Apap
Oxycodone Hcl/Acetaminophen	Primalev
Oxycodone Hcl/Acetaminophen	Perloxx
Oxycodone Hcl/Acetaminophen	Alcet
Oxycodone Hcl/Acetaminophen	Lynox
Oxycodone Hcl/Acetaminophen	Narvox
Oxycodone Hcl/Aspirin	Oxycodone Hcl-Aspirin
Oxycodone Hcl/Aspirin	Endodan
Oxycodone Hcl/Aspirin	Percodan
Oxycodone Hcl/Oxycodon Ter/Asa	Sk-Oxycodone W/Aspirin
Oxycodone Hcl/Oxycodon Ter/Asa	Roxiprin
Oxycodone Hcl/Oxycodon Ter/Asa	Oxycodone W/Aspirin
Oxycodone Hcl/Oxycodon Ter/Asa	Percodan
Oxycodone Hcl/Oxycodon Ter/Asa	Oxycodone-Aspirin
Oxycodone Hcl/Oxycodon Ter/Asa	Endodan
Oxycodone/Aspirin	Oxycodone W/Aspirin Half-Str
Oxycodone/Aspirin	Percodan Demi
Nitazoxanide	
Nitazoxanide	Alinia
Sucralfate	
Sucralfate	Carafate
Sucralfate	Sucralfate

Appendix C. Specifications Defining Parameters for this Request

Modular Program #9, version 2.0, was used to investigate prevalence and incidence of eight drug products in the infant population. The query period was from January 1, 2000 to December 31, 2012, and the enrollment gap was set at 45 days. Age groups were split as follows: 0-<12 and 12-<24 months. The 0-<12 month group was further stratified by months: 0-<1, 1-<3, 3-<6, 6-<12 months. This report examines 16 scenarios with differing exposures of interest that require both medical and drug coverage. A second report examines 16 scenarios with differing exposures of interest that require drug coverage only. See below for a description of each of the scenarios evaluated in this report.

Drug/Exposure Criteria					
Scenario	Incident exposure	Coverage Requirement	Incident with respect to (incidence criteria):	Washout (days)	Washout Type*
Age Group = 0- <12, 12-<24 months					
1	Acetaminophen with codeine	Drug and Medical	Acetaminophen with codeine	1	MIN
2	Acyclovir/acyclovir sodium	Drug and Medical	Acyclovir/acyclovir sodium	1	MIN
3	Nizatidine	Drug and Medical	Nizatidine	1	MIN
4	Albuterol/albuterol sulfate	Drug and Medical	Albuterol/albuterol sulfate	1	MIN
5	Levalbuterol HCl/Levalbuterol tartrate	Drug and Medical	Levalbuterol HCl/Levalbuterol tartrate	1	MIN
6	Oxycodone HCl	Drug and Medical	Oxycodone HCl	1	MIN
7	Nitazoxanide	Drug and Medical	Nitazoxanide	1	MIN
8	Sucralfate	Drug and Medical	Sucralfate	1	MIN
Age Group = 0-<1, 1-<3, 3-<6, 6-<12 months					
9	Acetaminophen with codeine	Drug and Medical	Acetaminophen with codeine	1	MIN
10	Acyclovir/acyclovir sodium	Drug and Medical	Acyclovir/acyclovir sodium	1	MIN
11	Nizatidine	Drug and Medical	Nizatidine	1	MIN
12	Albuterol/albuterol sulfate	Drug and Medical	Albuterol/albuterol sulfate	1	MIN
13	Levalbuterol HCl/Levalbuterol tartrate	Drug and Medical	Levalbuterol HCl/Levalbuterol tartrate	1	MIN
14	Oxycodone HCl	Drug and Medical	Oxycodone HCl	1	MIN
15	Nitazoxanide	Drug and Medical	Nitazoxanide	1	MIN
16	Sucralfate	Drug and Medical	Sucralfate	1	MIN

*A "minimum" washout type for the exposure will only consider the first incident exposure (dispensings/procedures) for each member over the member's entire enrollment history. There can be at most one incident exposures (dispensings/procedures) per member. The enrollment requirement is based on the number of days in the washout.